Drug Sponsors

Roche forms alliance with med fusion

Wednesday, June 6, 2012 12:45 PM

Roche has formed a strategic alliance with med fusion of Lewisville, Texas, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

More... »

ISTA stockholders approve acquisition by Bausch + Lomb

Wednesday, June 6, 2012 10:05 AM

At a special meeting on Tuesday, June 5, ISTA Pharmaceuticals stockholders voted to approve the merger of ISTA and Bausch & Lomb.

More... »

Quest PharmaTech receives $8 million investment for oregovomab trials

Wednesday, June 6, 2012 09:32 AM

Quest PharmaTech, an Alberta-based biotech developing and commercializing products for the treatment of cancer, has received an $8 million investment from parties of South Korea to support its clinical trial programs.

More... »

Astellas opens new headquarters in Illinois, creates 150 jobs

Tuesday, June 5, 2012 08:01 AM

Astellas Pharma U.S., subsidiary of Tokyo-based Astellas Pharma, has opened its new headquarters in Glenview, Ill., serving the Americas.

More... »

Emergent BioSolutions secures funding from BARDA for anthrax vaccine

Monday, June 4, 2012 11:33 AM

Emergent BioSolutions of Rockville, Md., has reached an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a non-interference study to be used to support a post-exposure prophylaxis (PEP) indication for BioThrax, an adsorbed anthrax vaccine.

More... »

Alize Pharma closes $4.1 million funding round

Monday, June 4, 2012 11:14 AM

Alize Pharma, a group of companies developing drugs for the treatment of metabolic diseases and cancer, has completed a funding round of $4.1 million, which will enable the company to move AZP-531, its UAG (UnAcylated Ghrelin) analog, into phase I clinical trials.

More... »

GSK’s Hart-Scott-Rodino waiting period expires for HGS tender offer

Monday, June 4, 2012 10:55 AM

GlaxoSmithKline’s waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, expired as of June 1, 2012, giving GSK clearance to acquire all outstanding shares of Human Genome Sciences.

More... »

Ariana expands operations to U.S.

Monday, June 4, 2012 09:54 AM

France-based Ariana Pharma, a provider of “non-statistical” clinical data analysis technology to the pharmaceutical industry, has expanded its global operations by establishing a permanent U.S. office in Cambridge, Mass., to service growing demand for its powerful data analytics technology KEM.  

More... »

Goodwin Biotech, MD Anderson collaborate on GMP manufacturing of fusion protein conjugate

Monday, June 4, 2012 09:40 AM

Goodwin Biotechnology (GBI) of Plantation, Fla., and the University of Texas MD Anderson Cancer Center have collaborated on process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator.

More... »

CDRD, CDRD Ventures, GSK collaborate to advance Canadian health research

Friday, June 1, 2012 03:07 PM

The Centre for Drug Research and Development (CDRD), its commercial arm, CDRD Ventures (CVI), and global pharmaceutical company GlaxoSmithKline (GSK) in have entered into a strategic collaboration that will provide new financial resources as well as leading drug development expertise to be applied to the development and commercialization of health research conducted in Canadian research institutions.

More... »